Cost Of Revenue - Ryvu Therapeutics SA (WSE:RVU) - Alpha Spread
R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 54.2 PLN -0.18% Market Closed
Market Cap: 1.3B PLN
Have any thoughts about
Ryvu Therapeutics SA?
Write Note

Ryvu Therapeutics SA
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ryvu Therapeutics SA
Cost of Revenue Peer Comparison

Comparables:
I
IGN
M
MDB
S
SLV

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
R
Ryvu Therapeutics SA
WSE:RVU
Cost of Revenue
-zł24m
CAGR 3-Years
-28%
CAGR 5-Years
18%
CAGR 10-Years
N/A
I
Inno-Gene SA
WSE:IGN
Cost of Revenue
-zł666k
CAGR 3-Years
51%
CAGR 5-Years
-6%
CAGR 10-Years
13%
M
Medicofarma Biotech SA
WSE:MDB
Cost of Revenue
-zł259.4k
CAGR 3-Years
55%
CAGR 5-Years
41%
CAGR 10-Years
N/A
S
Selvita SA
WSE:SLV
Cost of Revenue
-zł68.6m
CAGR 3-Years
-7%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Ryvu Therapeutics SA's Cost of Revenue?
Cost of Revenue
-24m PLN

Based on the financial report for Mar 31, 2024, Ryvu Therapeutics SA's Cost of Revenue amounts to -24m PLN.

What is Ryvu Therapeutics SA's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
18%

Over the last year, the Cost of Revenue growth was 5%. The average annual Cost of Revenue growth rates for Ryvu Therapeutics SA have been -28% over the past three years , 18% over the past five years .

Back to Top